Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of melflufen + dexamethasone versus pomalidomide + dexamethasone in lenalidomide-refractory relapsed/refractory multiple myeloma
MOH_2017-06-08_000432Phase 3Recruiting
- Sponsor
- Oncopeptides AB
- Start
- Mar 2017
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Molecular Glues → Targeted Protein Degraders (TPDs) → Small Molecules, Peptide-Drug Conjugates → Peptide Conjugates → Peptides
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in multiple myeloma (MM) comparing melflufen + dexamethasone with pomalidomide + dexamethasone (2 arms). Primary endpoint: Progression-free survival. Started Mar 2017; status: recruiting.
02
Drugs
melphalan flufenamidepomalidomidedexamethasone
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on MOH_2017-06-08_000432.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2017-06-08_000432.